Filing Details

Accession Number:
0001209191-17-006695
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-02-01 16:22:30
Reporting Period:
2017-01-31
Filing Date:
2017-02-01
Accepted Time:
2017-02-01 16:22:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1370053 Anaptysbio Inc ANAB Pharmaceutical Preparations (2834) 203828755
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1388325 A/s Novo Tuborg Havnevej 19
Hellerup G7 2900
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-01-31 1,428,571 $0.00 1,428,571 No 4 C Direct
Common Stock Acquisiton 2017-01-31 486,820 $0.00 1,915,391 No 4 C Direct
Common Stock Acquisiton 2017-01-31 312,986 $0.00 2,228,377 No 4 C Direct
Common Stock Acquisiton 2017-01-31 673,454 $0.00 2,901,831 No 4 C Direct
Common Stock Acquisiton 2017-01-31 81,673 $0.00 2,983,504 No 4 X Direct
Common Stock Acquisiton 2017-01-31 50,000 $15.00 3,033,504 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 X Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2017-01-31 1,428,571 $0.00 1,428,571 $0.00
Common Stock Series C Preferred Stock Disposition 2017-01-31 486,820 $0.00 486,820 $0.00
Common Stock Series C-1 Preferred Stock Disposition 2017-01-31 312,986 $0.00 312,986 $0.00
Common Stock Series D Preferred Stock Disposition 2017-01-31 673,454 $0.00 673,454 $0.00
Common Stock Series C Preferred Stock Warrant (Right to Buy) Disposition 2017-01-31 117,235 $0.00 117,235 $4.55
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 2018-11-04 No 4 X Direct
Footnotes
  1. The Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock (the "Preferred Stock") had no expiration date and was convertible at any time at the holder's election. Immediately prior to the closing of the Issuer's initial public offering (the "IPO Closing"), the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock.
  2. Immediately prior to the IPO Closing, the warrant became exercisable for shares of common stock. The shares acquired upon exercise of the warrant were acquired through a net exercise procedure in accordance with the terms of the warrant and did not involve any sale of shares. All shares received upon such exercise are subject to a lock-up agreement between the Reporting Person and the underwriters.
  3. Represents a purchase from the underwriters in the Issuer's initial public offering.